Supposed pituitary-production of human chorionic Gonadotropin induced by androgen deprivation therapy

Detalhes bibliográficos
Autor(a) principal: Yoshimura,Koji
Data de Publicação: 2019
Outros Autores: Nakashima,Yoshiharu, Sugiyama,Kyohei, Kohei,Naoki, Takizawa,Akitoshi
Tipo de documento: Artigo
Idioma: eng
Título da fonte: International Braz J Urol (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382019000100038
Resumo: ABSTRACT Introduction: The main cause of slightly elevated human chorionic gonadotropin (HCG) after successful treatment of male germ cell tumors is considered to be pituitary-derived HCG. It is well known that pituitary-derived HCG is frequently detected in postmenopausal women. We evaluated the status of serum HCG in men with elevated gonadotropins, which were induced by androgen deprivation therapy, using commercially available assays. Materials and Methods: We enrolled 44 patients with prostate cancer, who underwent luteinizing-hormone releasing hormone agonist treatment. We measured serum follicle-stimulating hormone (FSH), serum luteinizing hormone (LH), serum total HCG, serum free HCG-β subunit, and urine total HCG 3 times per patient, on the day of treatment initiation, the next day, and 3 months after. Results: On the day after treatment initiation, serum and urine HCG was detected in 61% and 73% of patients, respectively. Markedly strong correlations were observed between serum/urine HCG and FSH/LH. In particular, receiver operating characteristic curve analysis indicated excellent area under the curve (0.977, 95% confidence interval 0.951–1.003)) for serum HCG-detectable LH. At the cutoff value of 21.07 mIU/mL for serum HCG-detectable LH, the sensitivity and specificity were 96.7% and 95.3%, respectively. Serum HCG-β was not detectable at any times in any patients. Conclusions: Suggested pituitary-derived HCG can be frequently detected in patients with elevated gonadotropins, and there is a firm association between HCG detection and gonadotropin levels.
id SBU-1_74e6f8464eb37f7725cfd150fbac789e
oai_identifier_str oai:scielo:S1677-55382019000100038
network_acronym_str SBU-1
network_name_str International Braz J Urol (Online)
repository_id_str
spelling Supposed pituitary-production of human chorionic Gonadotropin induced by androgen deprivation therapyChorionic GonadotropinNeoplasms, Germ Cell and EmbryonalAndrogensLuteinizing HormoneABSTRACT Introduction: The main cause of slightly elevated human chorionic gonadotropin (HCG) after successful treatment of male germ cell tumors is considered to be pituitary-derived HCG. It is well known that pituitary-derived HCG is frequently detected in postmenopausal women. We evaluated the status of serum HCG in men with elevated gonadotropins, which were induced by androgen deprivation therapy, using commercially available assays. Materials and Methods: We enrolled 44 patients with prostate cancer, who underwent luteinizing-hormone releasing hormone agonist treatment. We measured serum follicle-stimulating hormone (FSH), serum luteinizing hormone (LH), serum total HCG, serum free HCG-β subunit, and urine total HCG 3 times per patient, on the day of treatment initiation, the next day, and 3 months after. Results: On the day after treatment initiation, serum and urine HCG was detected in 61% and 73% of patients, respectively. Markedly strong correlations were observed between serum/urine HCG and FSH/LH. In particular, receiver operating characteristic curve analysis indicated excellent area under the curve (0.977, 95% confidence interval 0.951–1.003)) for serum HCG-detectable LH. At the cutoff value of 21.07 mIU/mL for serum HCG-detectable LH, the sensitivity and specificity were 96.7% and 95.3%, respectively. Serum HCG-β was not detectable at any times in any patients. Conclusions: Suggested pituitary-derived HCG can be frequently detected in patients with elevated gonadotropins, and there is a firm association between HCG detection and gonadotropin levels.Sociedade Brasileira de Urologia2019-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382019000100038International braz j urol v.45 n.1 2019reponame:International Braz J Urol (Online)instname:Sociedade Brasileira de Urologia (SBU)instacron:SBU10.1590/s1677-5538.ibju.2017.0654info:eu-repo/semantics/openAccessYoshimura,KojiNakashima,YoshiharuSugiyama,KyoheiKohei,NaokiTakizawa,Akitoshieng2019-03-18T00:00:00Zoai:scielo:S1677-55382019000100038Revistahttp://www.brazjurol.com.br/ONGhttps://old.scielo.br/oai/scielo-oai.php||brazjurol@brazjurol.com.br1677-61191677-5538opendoar:2019-03-18T00:00International Braz J Urol (Online) - Sociedade Brasileira de Urologia (SBU)false
dc.title.none.fl_str_mv Supposed pituitary-production of human chorionic Gonadotropin induced by androgen deprivation therapy
title Supposed pituitary-production of human chorionic Gonadotropin induced by androgen deprivation therapy
spellingShingle Supposed pituitary-production of human chorionic Gonadotropin induced by androgen deprivation therapy
Yoshimura,Koji
Chorionic Gonadotropin
Neoplasms, Germ Cell and Embryonal
Androgens
Luteinizing Hormone
title_short Supposed pituitary-production of human chorionic Gonadotropin induced by androgen deprivation therapy
title_full Supposed pituitary-production of human chorionic Gonadotropin induced by androgen deprivation therapy
title_fullStr Supposed pituitary-production of human chorionic Gonadotropin induced by androgen deprivation therapy
title_full_unstemmed Supposed pituitary-production of human chorionic Gonadotropin induced by androgen deprivation therapy
title_sort Supposed pituitary-production of human chorionic Gonadotropin induced by androgen deprivation therapy
author Yoshimura,Koji
author_facet Yoshimura,Koji
Nakashima,Yoshiharu
Sugiyama,Kyohei
Kohei,Naoki
Takizawa,Akitoshi
author_role author
author2 Nakashima,Yoshiharu
Sugiyama,Kyohei
Kohei,Naoki
Takizawa,Akitoshi
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Yoshimura,Koji
Nakashima,Yoshiharu
Sugiyama,Kyohei
Kohei,Naoki
Takizawa,Akitoshi
dc.subject.por.fl_str_mv Chorionic Gonadotropin
Neoplasms, Germ Cell and Embryonal
Androgens
Luteinizing Hormone
topic Chorionic Gonadotropin
Neoplasms, Germ Cell and Embryonal
Androgens
Luteinizing Hormone
description ABSTRACT Introduction: The main cause of slightly elevated human chorionic gonadotropin (HCG) after successful treatment of male germ cell tumors is considered to be pituitary-derived HCG. It is well known that pituitary-derived HCG is frequently detected in postmenopausal women. We evaluated the status of serum HCG in men with elevated gonadotropins, which were induced by androgen deprivation therapy, using commercially available assays. Materials and Methods: We enrolled 44 patients with prostate cancer, who underwent luteinizing-hormone releasing hormone agonist treatment. We measured serum follicle-stimulating hormone (FSH), serum luteinizing hormone (LH), serum total HCG, serum free HCG-β subunit, and urine total HCG 3 times per patient, on the day of treatment initiation, the next day, and 3 months after. Results: On the day after treatment initiation, serum and urine HCG was detected in 61% and 73% of patients, respectively. Markedly strong correlations were observed between serum/urine HCG and FSH/LH. In particular, receiver operating characteristic curve analysis indicated excellent area under the curve (0.977, 95% confidence interval 0.951–1.003)) for serum HCG-detectable LH. At the cutoff value of 21.07 mIU/mL for serum HCG-detectable LH, the sensitivity and specificity were 96.7% and 95.3%, respectively. Serum HCG-β was not detectable at any times in any patients. Conclusions: Suggested pituitary-derived HCG can be frequently detected in patients with elevated gonadotropins, and there is a firm association between HCG detection and gonadotropin levels.
publishDate 2019
dc.date.none.fl_str_mv 2019-01-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382019000100038
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382019000100038
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/s1677-5538.ibju.2017.0654
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Urologia
publisher.none.fl_str_mv Sociedade Brasileira de Urologia
dc.source.none.fl_str_mv International braz j urol v.45 n.1 2019
reponame:International Braz J Urol (Online)
instname:Sociedade Brasileira de Urologia (SBU)
instacron:SBU
instname_str Sociedade Brasileira de Urologia (SBU)
instacron_str SBU
institution SBU
reponame_str International Braz J Urol (Online)
collection International Braz J Urol (Online)
repository.name.fl_str_mv International Braz J Urol (Online) - Sociedade Brasileira de Urologia (SBU)
repository.mail.fl_str_mv ||brazjurol@brazjurol.com.br
_version_ 1750318076713238528